COSMOS HEALTH INC (COSM)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
$0.31+10.95%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
Research Workspace
Put COSM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 34% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementThis stock is highly volatile — it swings about 5% on a typical day and fell roughly 81% in its worst 12-month stretch.
View RiskCOSM’s case rests on expanding U.S. sales, though the desk has no earnings history. Recent company-reported sales rates support that growth claim, but no earnings release is recorded. The valuation bridge and priced-in expectations are omitted, so the market’s growth assumptions cannot be assessed. Unprofitability leaves earnings quality unassessable, and our model puts the next-quarter miss probability near 48%. Peer multiples imply no available valuation read; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. COSM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering COSM (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare COSM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| COSM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put COSM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand U.S. market presence
E-commerce expansion adds international reach, but does not directly establish U.S. growth or revenue targets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Expand U.S. market presence
Record sales indicate strong U.S. market presence growth.
Advances: Expand U.S. market presence
Manufacturing deal supports U.S. market expansion objective.
Advances: Reach $155.8 million revenue by 2027
Projected revenue supports growth objective for 2027.
Threatens: Reach $155.8 million revenue by 2027
Earnings miss indicates difficulty in reaching revenue target.
Manufacturing deal supports revenue growth objective.
Advances: Expand U.S. market presence
Launch of Oliv18 directly expands U.S. market presence.
Advances: Reach $155.8M revenue by 2027
Q1 revenue growth supports revenue target for 2027.